Introduction
============

Unlike resource limited countries, access to essential medicines is well-established in high income countries ([@B24]). The concept of essential medicines for high income countries is though still controversial ([@B24]; [@B6]). However, there have been good examples such as the 'Wise List' in Stockholm County Council, Sweden, with high adherence to a limited list of medicines that cover over 90% of the needs of patients in ambulatory care ([@B23]; [@B3]; [@B8]). These high adherence rates in Sweden have been achieved through the introduction of robust processes for medicine selection coupled with a comprehensive communication program ([@B20]; [@B3]; [@B8], [@B9]). Similar examples exist in other countries ([@B3]). Having said this, providing medicines which meet the priority needs of the community through reliable health systems was a key principal for access to medicines ([@B24]).

Access to medicines can be assessed by their availability and affordability ([@B55]). Availability refers to marketing authorization, available stocks, and distribution ([@B56]; [@B7]); with affordability closely related to the price of medicines and economic subsidies of healthcare systems. More specifically, copayments for medicines directly affects the use of medicines ([@B21]; [@B45]; [@B47]; [@B26]), with the degree of coverage for pharmaceuticals depending on the country, the types of medicines and the socioeconomic status of the beneficiaries ([@B36]; [@B35]).

Korea is a country that achieved universal health coverage in 1989. As the growth of pharmaceutical expenditure in Korea has been greater than other health expenditures (16.3 vs. 15.2% as of 2006), and the portion of drug spending to total health expenditures was greater (21.4% as of 2015) compared to OECD countries (16.3%) ([@B39]; [@B33]), policy makers and regulators in Korea have mainly focused on drug cost containment policies in recent years. As part of this process, a positive list system (PLS) was introduced in 2007 to select medicines to be reimbursed based on their cost-effectiveness to the National Health Insurance (NHI). Since the introduction of the PLS, non-reimbursable medicines have been officially allowed to be prescribed with no restrictions but associated with co-payments. In particular, high cost medicines, which hardly met the agreed incremental cost-effectiveness ratio (ICER) threshold were not reimbursed but could still be prescribed for treatment with the costs charged to the patient. As a result, issues of patients' access to medicines have been raised especially for high cost medicines such as anticancer agents and those for rare diseases where co-payments are an issue ([@B25]). This controversy has influenced Korean drug policy with the government now taking a more liberal attitude towards selecting medicines for reimbursement through measures including a flexible application of ICER thresholds, the exemption of cost-effectiveness appraisals for some medicines, exemptions of price negotiations for some medicines as well as the introduction of risk sharing arrangements ([@B31]; [@B32]). Despite these measures, patients' advocacy groups and pharmaceutical companies are still appealing to switch back to the negative list system under the name of patient's rights of access to medicines ([@B25]).

For the interest on public health, conditional approval can be available when the benefit of the immediate availability of medicines outweighs the risk with less comprehensive data than is normally required based on marketing authorization guidelines. The European Medicines Agency (EMA) grants conditional approval for medicines that are aimed at treating, preventing, or diagnosing, seriously debilitating or life-threatening diseases or intended for use in emergency situations or designated as orphan medicines ([@B13], [@B12]). Consequently, medicines with a conditional approval were seen as urgently addressing the unmet needs of patients and/or the treatment of severe conditions. These medicines were selected as a subject to address access to medicine issues in Korea given the ongoing controversies that exist in Korea.

In view of this, the purpose of this study is to explore the availability and affordability of EMA's recently approved medicines with a conditional approval in Korea by comparing the situation in Korea with 11 other countries that are typically referenced by Korea. Subsequently, to review the findings and their implications for the Korean pharmaceutical pricing and reimbursement system in light of their access to medicines. Having said this, there have been concerns with the conditional authorization system in Europe ([@B2]). The conditional approval system is different to the recently discussed EMA Adaptive Pathways process intended to also accelerate the uptake of new innovative medicines into routine clinical care in Europe, where there have also been concerns ([@B10]; [@B51]).

Materials and Methods {#s1}
=====================

Study Subjects
--------------

Considering the severity of diseases and importance of access to new innovative medicines that appear to address unmet need in these critical areas, we collected the list of medicines with conditional approval by EMA from 2014 to 2017 ([@B11]). If these medicines are approved and reimbursed given typically limited clinical data, this would suggest high levels of availability and affordability of new premium priced medicines. Accordingly, a total 14 drugs were selected for this study, and of these all were designated as orphan drugs as well-except for the Pandemic Flu vaccine. We subsequently excluded the Pandemic Flu Vaccine because it is not part of the NHS system in some countries, i.e., the influenza vaccine was provided via the National Immunization Program, which is funded by a general tax in Korea, Japan and Taiwan ([@B34]; [@B27]; [@B48]; [@B46]), and it is currently not reimbursed among a high number of countries involved in this research. This left 13 medicines for analysis.

Country Comparison
------------------

Access to the selected medicines in 12 countries were compared. These countries were the United States, United Kingdom, France, Germany, Switzerland, Italy, Japan, Canada, Taiwan, Australia, New Zealand, and Korea. They were specifically chosen as most of them are officially referenced by the Korean reimbursement and pricing authorities. In addition, all countries except the United States ensure access to medicines through their national healthcare systems.

We searched official websites of each country to collect information on market approval, reimbursement status and the fixed prices of the selected medicines prior to any confidential discount.

Availability: Approval and Time Lag to Approval
-----------------------------------------------

Marketing approval is the first step to launching new medicines across countries. Without market authorization, medicines are not available in a country. For the EU (European Union) member countries, approval of medicines is typically made by the EMA through a centralized process. All other countries have their own authorities for the marketing authorization of medicines such as the Food and Drug Administration (FDA) for United States and the Ministry of Food, Drug and Safety (MFDS) for Korea. We checked the approval rate of the selected medicines for all countries except European countries.

We also checked the moment of licensing in other than EU countries and calculated the time lag to approval on the basis of EMA's approval date. Although market authorization applications are initiated by manufacturers, time lag to approval represents the delay of the availability of these new medicines across countries.

Affordability: Reimbursement Status and Prices
----------------------------------------------

Reimbursement status and prices of the selected medicines were considered as proxies of affordability. However, we are aware that the different countries have different processes and systems for the pricing and reimbursement of medicines including whether reimbursed prices are based on the perceived level of innovation versus current standards or economic measures such as ICERs with or without agreed threshold levels ([@B40]; [@B18], [@B22]; [@B54]). Whether the medicines were listed by national healthcare system was checked from the public information sources (see **Box [1](#BX1){ref-type="boxed-text"}**). For the United States, we checked both the Redbook and the Federal Supply Schedule (FSS).

###### Box 1. Data source.

  Country          Source                                        Type of prices
  ---------------- --------------------------------------------- -------------------------------------------------------------------------------------------
  United Kingdom   MIMS                                          Ex-factory pharmacy price ([@B42])
  United States    Redbook                                       Ex-factory pharmacy price ([@B42])
                   FSS                                           Contract price for qualified government ([@B38])
  France           VIDAL                                         Ex-factory wholesale price ([@B42])
  Italy            www.codifa. it (L'Informatore Farmaceutico)   Ex-factory wholesale price ([@B42]) Ex-factory hospital price for hospital drugs ([@B42])
  Germany          Rote-Liste                                    Ex-factory wholesale price ([@B41])
  Swiss            Federal Office for Public Health              Ex-factory wholesale price ([@B42])
  Canada           Ontario drug benefit formulary                Ex-factory price ([@B37])
  Australia        PBS                                           Dispensed price for maximum amount ([@B1])
  New Zealand      Pharmac                                       Ex-factory price ([@B44])
  Japan            MHLW                                          Ex-factory pharmacy price ([@B49])
  Taiwan           NHIA                                          Public Price
  Korea            HIRA                                          Ex-factory pharmacy price
                                                                 

MIMS, Monthly Index of Medical Specialties; FSS, Federal supply schedule; PBS, Pharmaceutical Benefits Scheme; Pharmac, Pharmaceutical management agency; MHLW, Ministry of Health, Labour and Welfare; NHIA, National Health Insurance Administration; HIRA, Health Insurance Review & Assessment Service.

For price comparisons, we used public prices for reimbursed medicines. Public prices do not generally reflect effective prices since substantial rebates or discounts are being offered to insurers in many countries to enhance reimbursement for new premium priced medicines. These confidential arrangements between manufacturers and payers are increasingly practiced ([@B53]; [@B16], [@B15]; [@B14]; [@B43]). However, published prices are the only publicly available information for price comparisons. We compared prices of the selected medicines with this limitation and careful interpretation. Each country publishes prices online and types of prices are different, for examples, ex-factory prices, ex-factory wholesale price and ex-factory pharmacy price. Types of price and the source of price information for each country are shown in **Box [1](#BX1){ref-type="boxed-text"}**.

Results
=======

**Table [1](#T1){ref-type="table"}** shows the brand-name with active pharmaceutical ingredients and the main indications of the 13 selected medicines approved by EMA during 2014--2017. As of March 16, 2018, the average number of countries in which the selected medicines were licensed was three out of eight (except four European countries). Blinatumomab (Blincyto^TM^) and Ixazomib (Ninlaro^TM^) had been approved in six countries while Holoclar^TM^, Translarna^TM^ (Ataluren), and Zalmoxis^TM^ were not yet approved. Blinatumomab was listed in eight countries while Zalmoxis^TM^ was not yet reimbursed.

###### 

Basic information of the selected medicines.

  Brandname        API                                   Main indication               Approval date(EMA)   No. of authorized countries^a^   No. of reimbursed countries^b^
  ---------------- ------------------------------------- ----------------------------- -------------------- -------------------------------- --------------------------------
  Bavencio^TM^     Avelumab                              MCC                           18 September 2017    9 (5)                            5 (41.7%)
  Blincyto^TM^     Blinatumomab                          ALL                           23 November 2015     10 (6)                           8 (66.7%)
  Cometriq^TM^     Cabozantinib                          Medullary thyroid carcinoma   21 March 2014        8 (4)                            6 (50.0%)
  Deltyba^TM^      Delamanid                             MDR-TB                        23 April 2014        6 (2)                            6 (50.0%)
  Holoclar^TM^     human corneal cells with stem cells   limbal stem cell deficiency   17 February 2015     4 (0)                            2 (16.7%)
  Lartruvo^TM^     Olaratumab                            soft tissue sarcoma           9 November 2016      8 (4)                            6 (50.0%)
  Natpar^TM^       Parathyroid hormone                   chronic hypoparathyroidism    24 April 2017        5 (1)                            3 (25.0%)
  Ninlaro^TM^      Ixazomib                              multiple myeloma              21 November 2016     10 (6)                           6 (50.0%)
  Ocaliva^TM^      Obeticholic acid                      primary biliary cholangitis   12 December 2016     5 (1)                            5 (41.7%)
  Sirturo^TM^      Bedaquiline                           MDR-TB                        5 March 2014         9 (5)                            6 (50.0%)
  Translarna^TM^   Ataluren                              Duchenne muscular dystrophy   31 July 2014         4 (0)                            4 (33.3%)
  Venclyxto^TM^    Venetoclax                            CLL                           5 December 2016      9 (5)                            5 (41.7%)
  Zalmoxis^TM^     Allogeneic T cells                    HSCT                          18 Auguest 2016      4 (0)                            0 (0.0%)
                                                                                                                                             

MDR-TB, multidrug resistant tuberculosis; ALL, acute lymphoblastic leukemia; HSCT, haploidentical haematopoietic stem cell transplantation; CLL, chronic lymphocytic leukaemia; MCC, metastatic Merkel cell carcinoma.

a

Maximum number of countries is 12 and 8 between brackets, which excluded EU countries.

b

Number of countries where the selected medicines were reimbursed, % out of 12 in brackets.

Approvals by County
-------------------

On average, there was a 31.9% approval rate for the 13 medicines for all countries except the EU countries. The approval status for each country is depicted in **Figure [1](#F1){ref-type="fig"}**. As EMA approval was a reference, all the included EU countries had approval for the 13 medicines while Switzerland had approved only six medicines. The highest rate of approval was shown in United States (69.2%, 9 out of 13) followed by Korea (46.2%) and Switzerland (46.2%, 6 out of 13 products). Taiwan and New Zealand showed the lowest approval rate of 15.4% (2 out of 13 products). Among Asia pacific countries, Korea was a country where more medicines were available than other countries.

![Number of approved medicines and approval rates by country. NB: Brackets = % of approved medicines out of 13.](fphar-09-00938-g001){#F1}

Time Lag to Approval
--------------------

As shown in **Figure [2](#F2){ref-type="fig"}**, the time lag to approval was calculated on the basis of EMA's approval date and compared among the eight other target countries. An average of 238 days (median: +120 days) were taken among the countries for approval. The United States (median: -355 days) was the country where all medicines were most rapidly approved followed by Canada (median: +29 days) and Japan (median: +98 days).

![Box-plot of time lag to approval on the basis of EMA (Maximum, Median, Minimum values).](fphar-09-00938-g002){#F2}

Korea (median: +152 days) was ranked the fifth most rapidly approving country. Unlike EU countries, Switzerland had taken a relatively long time for approval. Taiwan and New Zealand showed 603 and 614.5 days respectively for the time lag from the EMA. Korea, Japan, and Autralia had the greatest variations between maximum and minimum values while the United States received FDA's approval before the EMA's approval date. Unlike the approval rate, Korea took a relatively long time to approve the selected medicines compared to Japan and Australia.

Reimbursement Status
--------------------

Among the approved medicines, an average reimbursement rate for the 12 countries was 54.4%. Although all medicines were approved in European countries, listing (reimbursement) rates varied greatly across the countries as shown in **Figure [3](#F3){ref-type="fig"}**. Germany (92.3% of the 13 medicines) showed a relatively high rate of reimbursement followed by the United Kingdom (76.9%) whereas Switzerland, whilst in Europe but not part of the EU, only reimbursed five out of six approved medicines (83.3%).

![Number of reimbursed medicines and listing rate by country. NB: Redbook was referenced for the United States and brackets = % of reimbursed (listed) medicines out of those approved.](fphar-09-00938-g003){#F3}

Overall, the United States ranked 100% of listing of the nine approved medicines based on the Redbook. However, eight out of nine medicines were listed in the FSS (88.9%). Germany (92.3%, 12 out of 13) ranked 2^nd^ followed by Switzerland (83.3%, five out of six), United Kingdom (76.9%, 10 out of 13), Japan (75.0%, three out of four), as well as France and Italy (69.2%, 9 out of 13). Korea ranked eighth with a listing rate of 66.7% (of 6) followed by Australia (25.0% of 4). Canada, Taiwan, and New Zealand listed none of the medicines. Within Asia-Pacific region, Japan showed the highest rate of reimbursement followed by Korea.

Price Comparisons
-----------------

**Figure [4](#F4){ref-type="fig"}** depicts the prices of each medicine for all the countries. Prices were adjusted with Purchasing Power Parity (PPP_USD). Although the types of prices differed by country and direct comparison was controversial, it was found that price dispersion was broad with some medicines such as Cabozantinib, Avelumab, Olaratumab and Obeticholic acid. However, there was limited price dispersion with Ataluren. The price dispersion, calculated by the maximum price divided by the minimum price, ranged from 1.1 to 3.1. Even in the same country such as the United States, the prices from the Redbook and FSS differed. On average, the Redbook prices (AWPs) were 1.7 times \[1.1∼1.8\] higher than the FSS prices. Price dispersion and the number of listed countries were significantly correlated (ρ = 0.704, *p* = 0.0072). Thus, the more countries the drug is listed, the greater the difference in drug prices. This proves that the one price policy of drug companies is not typically applied empirically.

![Prices of the medicines with a conditional approval (PPP_USD, Maximum, Median, Minimum values). Holoclar was not depicted as German price was unidentified. Its price of 120,396 (PPP) in Italy was not depicted.](fphar-09-00938-g004){#F4}

**Table [2](#T2){ref-type="table"}** shows the prices of four medicines listed in Korea compared to the other countries. Although direct comparisons of prices with different attributes should be done carefully, the price level of Korea was estimated with this limitation. The prices of Blinatumomab ranged from 0.8 to 1.6 times of the Korean price and those of Olaratumab ranged 1.3 to 2.4 times. For bedaquiline (0.8∼1.1 times) and delamanid (0.6∼1.4 times), Korean prices were found to be relatively high in consideration of compared countries' GDP level.

###### 

International price comparison of Korea's reimbursement drug (USD PPP).

  Countries             Bedaquiline   Delamanid   Blinatumomab   Olaratumab   Reference
  ----------- --------- ------------- ----------- -------------- ------------ --------------------------------
  US          Redbook   191 (1.1)     --          4,449 (1.6)    57.8 (2.4)   Ex-factory pharmacy price
              FSS       --            --          2,385 (0.8)    36.0 (1.5)   Contact price for government
  UK                    141 (0.8)     37 (0.8)    2,867 (1.0)    54.0 (2.2)   Ex-factory pharmacy price
  France                --            37 (0.8)    3,293 (1.2)    --           Ex-factory wholesale price
  Italy                 150 (0.8)     39 (0.9)    3,582 (1.3)    34.9 (1.4)   Ex-factory wholesale price
  Swiss                 --            --          2,321 (0.8)    --           Ex-factory wholesale price
  Germany               180 (1.0)     38 (0.8)    2,864 (1.0)    32.6 (1.3)   Ex-factory wholesale price
  Japan                 --            62 (1.4)    --             --           Ex-factory pharmacy price
  Australia             --            --          2,724 (1.0)    --           Dispensed price for max amount
  Korea                 180 (1)       45 (1)      2,822 (1)      24.2 (1)     Ex-factory pharmacy price
                                                                              

Discussion
==========

Access to medicines has been a common issue for among low and middle-income countries ([@B4]). Even high income countries are now struggling to fund new premium priced medicines whilst maintaining universal access, which has resulted in new models to improve their managed entry ([@B19], [@B18], [@B22]; [@B30]; [@B40]).

This study explored access to medicines, particularly issues surrounding the Korean context in terms of the availability and affordability of recently approved medicines in areas of high unmet need. Thirteen medicines with conditional approval in the EU were selected for their urgency and necessity to address patients' unmet needs, with a 37.5% approval rate among eight countries excluding the four European countries. An average time lag to approval was 238 days from EMA's approval date. The United States with a 69.2% approval rate was always a country that manufacturers attempted to obtain approval before EMA approval. Among the 13 EMA approved medicines, an average reimbursement rate for the 12 countries was 54.4%. Some countries including Australia, Canada, Taiwan, and New Zealand, tended to be laggards to approve and reimburse the selected medicines.

The range of prices was found to be broad among most of the researched medicines. This is contrary to a one price policy as a global pricing strategy ([@B57]; [@B58]), which has been often claimed by global pharmaceutical companies. However, some publications have shown considerable variation in the prices of patented medicines across countries ([@B28]; [@B52]), similar to our findings, with the price of medicines varying depending on issues such as national reimbursement policies and economic levels ([@B17]; [@B40]; [@B50]; [@B22]). In addition, as mentioned, we are seeing the rise in managed entry agreements across countries to increase access to new medicines, which often contain confidential discounts ([@B53]; [@B16], [@B15]; [@B22]; [@B14]; [@B43]) making price comparisons difficult.

Encouragingly, Korea ranked second in the approval rate of 46.5% excluding EU countries and fifth in the time lag of 152 days \[-20∼1,285\]. The reimbursement rate was 66.7% of the approved medicines, with the prices of the selected medicines neither high nor low in comparison with the other countries.

We are aware this study has limitations. Firstly, we selected medicines with a conditional approval. These medicines were considered exceptional compared to others, which normally go through standard procedures of marketing approval and reimbursement appraisal. As we explored the states of approval and reimbursement of these medicines across the board, it may be difficult to generalize the results to other medicines. Secondly, published price information differed across the countries and it can be problematic to directly compare them. However, we could not adjust prices for comparison especially as some countries adopt risk sharing schemes or clawback systems for new medicines and published prices do not reflect these adjusted prices ([@B16]; [@B14]). In view of this, we had to approximately compare Korean prices with others to find some implications. In addition, we did not consider other funds besides the pharmaceutical benefit schemes, e.g., Blinatumomab was not covered by Ontario Drug Benefit formulary although it did through NDFP (New Drug Fund Program) ([@B5]).

Nevertheless, this study demonstrated contradictory results to pharmaceutical company's one pricing strategy ([@B57]) since most of the studied medicines showed a wide range of price distribution except Ataluren. Our study though reconfirmed the strategy that pharmaceutical companies try to delay the launch of their new medicine in countries with traditionally low prices or even not market at all in countries that are referenced by other countries with larger markets ([@B28]; [@B52]; [@B58]), exacerbated particularly in Europe by extensive reference pricing across countries ([@B29]). The United States showed 100% reimbursement of approved medicines and the highest prices while Taiwan and New Zealand were delayed in both their approval and reimbursement of the selected medicines.

As a result, the availability and affordability of the selected medicines featured geographically different aspects. Asia-pacific countries that are mostly small markets, or try to attain lower prices, were delayed in their approval and reimbursement rates for these selected medicines compared to other continents. However, Korea performed better than other selected Asian-Pacific countries for these medicine, which is encouraging given ongoing concerns.

Conclusion
==========

Korea was found to be a country where marketing authorization for more these selected medicines with EMA conditional reimbursement tended to be made, and subsequent reimbursement and pricing were not rigid even generous compared to other Asian-pacific countries. As a result, contrasting with the arguments of patient's advocacy groups and pharmaceutical companies in Korea ([@B25]). Consequently, Korean drug benefit policies for listing and pricing did not appear to hinder access to medicines even with a conditional approval in comparison with other countries. This is to be encouraged.
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